Twelve million people in the UK and US are now on a GLP-1 medication (Ozempic, Wegovy, Mounjaro, Zepbound). That number is growing by 20 - 30% per year. A meaningful slice of them - predominantly women 35 - 60 - have seen rapid facial volume loss as a side effect, and they are actively looking for skincare and cosmetic solutions.
This is a real, growing customer segment with specific needs. It is also a category where the opportunism has been extreme. Here is how to tell the difference, and how to enter cleanly if your brand has a credible play.
What actually happens to the skin
Three physiological changes drive the "Ozempic face" phenomenon.
Rapid fat pad loss. The face has distinct fat compartments (malar, buccal, submental) that provide structural support. Rapid weight loss depletes them faster than the skin can remodel, creating the characteristic hollowness in the cheeks and temples.
Collagen and elastin depletion. The skin loses structural protein at roughly 1% per year in a stable-weight adult. During rapid GLP-1-induced loss, that rate can be 3 - 5x higher, concentrated in the face and neck because those tissues have higher metabolic turnover.
Hydration and barrier shifts. GLP-1 medications affect hydration at a systemic level. Patients commonly report drier skin, more sensitive skin, and a faster-ageing appearance even when weight loss is modest.
These are formulation problems with formulation solutions. They are not cured by a generic hyaluronic serum with a new label.
What credible brands are doing
Three approaches we are seeing from brands handling this seriously.
Targeted peptide formulations. Peptides that specifically support collagen synthesis (palmitoyl tripeptide-1, matrixyl-3000 variants) paired with bioavailable vitamin C and niacinamide at higher percentages than standard. The formulation targets the actual structural issue, not just surface hydration.
Hydration with restoration claims. Polyglutamic acid, ceramide complexes, and barrier-support ingredients designed for skin that is losing its native oil and water retention. Claims framed around skin-barrier restoration, not "plumping".
Routine design, not just SKUs. The credible brands are shipping 3 - 4 product routines with clear sequencing and progression, often paired with content that explains what to expect at month 3, month 6, month 9 of a GLP-1 course. This is product-as-protocol, and it earns trust.
What opportunism looks like
Three red flags for brands that are cashing in rather than serving the customer.
Using "Ozempic" as the keyword. Ozempic is a trademarked brand name for Novo Nordisk's semaglutide product for type 2 diabetes. Using it in your marketing in the UK will draw MHRA attention and potential cease-and-desist letters. Brands that are still doing this in 2026 are being reckless.
Claiming to "replace" or "offset" the weight loss effect. You cannot. This is a medicinal claim your cosmetic product cannot make. The ASA has upheld complaints on this exact framing and will continue to.
Relaunching existing SKUs with new copy only. If the product is literally unchanged and just has new marketing, your informed customer will spot it within one TikTok review. The brands that get away with nothing-changed relaunches in other categories will not get away with it here because the customer segment is both affluent and attentive.
The honest entry test
Before committing to a GLP-1-adjacent launch, three questions.
One. Can your formulation make a credible structural claim (collagen, elastin, peptides targeting dermal remodelling) or does it just hydrate? If the answer is hydrate-only, skip this category.
Two. Do you have a routine or a stack, or do you have a single hero SKU? Single SKUs do not build trust in this segment. A three-step minimum, with clear protocol guidance, is the entry bar.
Three. Are you prepared to speak to the actual use case without using trademarked medication names? "Skincare for rapid weight loss" is honest. "Ozempic skincare" is a lawyer letter waiting to be written.
The 2026 outlook
This category will continue to grow. By 2028, depending on which analyst report you believe, between 40 and 60 million people globally will be on a GLP-1 medication. The skincare implications are genuine and the commercial opportunity is real.
The brands that earn a position in this category in 2026 - credible formulations, honest claims, proper customer education - will own a meaningful slice of premium skincare for the next decade. The ones taking shortcuts will end up as the cautionary tale at the front of the next regulatory review.